MUNDELEIN, Ill.–(BUSINESS WIRE)–
Marathon Pharmaceuticals, LLC and Medline Industries, Inc. today announced that they have entered a collaboration to market and distribute ZiNGO® (lidocaine hydrochloride monohydrate, 0.5 mg) powder intradermal injection system, a needle-free, easy-to-use device that delivers a topical local anesthetic to manage venous access pain in as little as 1 to 3 minutes (analgesia diminishes within 10 minutes).
The collaboration leverages Marathon Pharmaceuticals’ expertise in specialty drug development and manufacturing and Medline’s strengths as a leading global distributor of medical supplies and clinical solutions. ZiNGO® is currently in use at several major children’s and academic hospitals. ZiNGO® is a hand-held device that, with the push of a button, delivers a 0.5 mg dose of powdered lidocaine into the skin via a needle-free helium-powered delivery system, numbing the site in just 1 to 3 minutes. ZiNGO® is sterile, for single-use and does not need to be refrigerated. ZiNGO® is for external use on intact skin only.
“Physicians look to innovative medical products to help ease patient discomfort in pursuit of their goal to deliver optimal care and to achieve the highest level of patient satisfaction. I was pleased to be a part of this important initiative for reducing pain and discomfort related to venipuncture and IV cannulation in children,” said William T. Zempsky, MD, Professor of Pediatrics and Division Head of Pain and Palliative Medicine at Connecticut Children’s Medical Center, who led pediatric clinical trials of ZiNGO®.
Both companies share a common vision to help health care providers provide a high level of patient care through innovative products, technologies and services. “Medline is the ideal partner to help healthcare providers access ZiNGO®. By providing quality services, clinical solutions and logistical expertise, Medline is the preferred provider for leading healthcare organizations and we are proud to work with its team to make ZiNGO® available across the nation,” said Tom Larson, Vice President, Commercial Operations, for Marathon Pharmaceuticals.
“We’re excited to be joining forces with Marathon Pharmaceuticals to bring healthcare professionals a unique lidocaine drug delivery system to help manage IV start and blood draw pain. ZiNGO® is a convenient and easy to use local topical anesthetic which is needle free, sterile, ready-to-use, disposable, provides analgesia in as little as 1-3 minutes and is stored at room temperature. As our customers require other options to help improve patient outcomes and satisfaction, they can be confident in our never-ending search for proven solutions,” said Luke Stevens, President, Nutrition and Pharmaceuticals Division of Medline.
According to a survey of 2,187 nurses, respondents indicated peripheral intravenous catheter placement pain was considered to be one of the leading causes of procedural pain in the hospital 1. “ZiNGO® is an important treatment option to help reduce the pain of intravenous catheter placement and venipuncture pain for our pediatric patients,” said Dr. Zempsky.
ZiNGO® is indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3-18 years of age.
ZiNGO® is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults.
DOSAGE AND ADMINISTRATION
Apply one ZiNGO® to the site planned for venipuncture or intravenous cannulation, 1-3 minutes prior to needle insertion
Perform the procedure within 10 minutes after ZiNGO® administration
Use ZiNGO® only on intact skin
For external use only
IMPORTANT SAFETY INFORMATION
ZiNGO® (lidocaine hydrochloride monohydrate) is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. It is for external use only and not to be used around the eyes or on body orifices, mucous membranes, or on areas with a compromised skin barrier. ZiNGO® should only be used on skin locations where an adequate seal can be maintained. Do not use if the device is dropped or the pouch is damaged or torn. Patients with severe hepatic disease or pseudocholinesterase deficiency, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations of lidocaine.
Patients with bleeding tendencies or platelet disorders could have a higher risk of superficial dermal bleeding.
The most common adverse reactions (5%) observed in clinical studies included skin reactions at the site of administration: erythema, petechiae, edema, and pruritus. Most adverse reactions in the ZiNGO® adult clinical studies were application-site related [i.e., hypoaesthesia (0% active treated subjects vs. 0.5% sham-placebo device), burning (0.5% active treated subjects vs. 0.4% sham-placebo device), and venipuncture site hemorrhage (0.4% active treated subjects vs. 1.7% sham-placebo device)] and the most common systemic adverse reaction was dizziness (0.9% of active treated subjects vs. 0.7% sham-placebo device). Most adverse reactions in the ZiNGO® pediatric clinical studies were application-site reactions (i.e., bruising, burning, pain, contusion, hemorrhage), occurring in 4% of the patients in each treatment group and the most common systemic adverse reactions were nausea (2%) and vomiting (1%).
Click here to: See Full Prescribing Information.
About Marathon Pharmaceuticals
Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.
As the nation’s largest privately held manufacturer and distributor of quality medical supplies and services, Medline offers healthcare products and services that drive value through tailored solutions across the continuum of care. Named one of the country’s “Best and Brightest Companies to Work For,” the company is headquartered in Mundelein, Ill. and has more than 1,200 dedicated sales representatives to support its broad product line and cost management services. For more information on Medline, go to www.medline.com orhttp://www.medline.com/social-media to connect with Medline on a variety of social media channels.
1 Papa AM, Zempsky WT. Nurse Perceptions of the Impact of Pediatric Peripheral Venous Access Pain on Nurse and Patient Satisfactions: Results of a National Survey. Advanced Emergency Nursing Journal. 2010; 32(3):226-233.
2 Zingo® (lidocaine hydrochloride monohydrate) powder intradermal injection system. [package insert]. Northbrook, IL: Marathon Pharmaceuticals; 2013.
- Health Care Industry